Physician profile
Ann L Stroh
NPI 1568585206
$64,795.32
in general payments reported to CMS, 2019-2025
26 companies · $22K in 2025
The $22K reported for 2025 was more than what 89% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.92 · 2021: $314 · 2022: $556 · 2023: $17K · 2024: $25K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $3,329 · Food and Beverage: $2,351 · Consulting Fee: $1,995 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,112.50 |
| Travel and Lodging | $3,329.44 |
| Food and Beverage | $2,351.30 |
| Consulting Fee | $1,995.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $61,849.59 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $1,703.08 | 2022-2025 | |
| Puma Biotechnology, INC. | $232.05 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.07 | 2019-2025 | Opdivo |
| Seagen INC. | $114.61 | 2022-2023 | Tivdak, Padcev |
| Merck Sharp & Dohme LLC | $95.05 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $86.84 | 2023-2025 | Enhertu, Tagrisso, Imfinzi |
| Leica Microsystems INC. | $83.23 | 2021 | |
| Janssen Biotech, INC. | $74.28 | 2022-2024 | Darzalex, Talvey, Tecvayli |
| Stemline Therapeutics INC. | $66.57 | 2023-2025 | Orserdu |
| Pfizer INC. | $62.08 | 2023-2025 | |
| Dilon Technologies, INC. | $48.52 | 2022 | |
| Exelixis INC. | $30.44 | 2025 | Cabometyx |
| Tempus Ai, INC | $24.50 | 2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $23.86 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $20.26 | 2023 | |
| Abbvie INC. | $19.15 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.49 | 2022 | |
| Celgene Corporation | $17.41 | 2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $16.88 | 2022 | |
| Glaxosmithkline, LLC. | $15.97 | 2022 | |
| Amgen INC. | $15.24 | 2022 | |
| Astellas Pharma US INC | $14.42 | 2023 | Xtandi |
| Genentech USA, INC. | $12.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.32 | 2022 | |
| Lilly USA, LLC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Stroh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.